Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
About
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Topics
- Location
- Boston, MA, United States
- Team size
- 15 employees
- YC batch
- Winter 2021
- Status
- Active
- Stage
- Early stage
